Gil Omenn

Last updated
Gilbert S. Omenn
Alma mater Princeton University, Harvard Medical School, University of Washington
Scientific career
FieldsGenetics, Public Health
Institutions University of Michigan.
External video
Nuvola apps kaboodle.svg "Distinguished University Professorship Lecture - Gilbert Omenn", University of Michigan, March 28, 2017.

Gilbert S. Omenn M.D., Ph.D. is an American medical doctor and researcher. He currently is the Harold T. Shapiro Distinguished University Professor at the University of Michigan; professor of Computational medicine & bioinformatics, Molecular medicine & genetics, Human genetics, and Public health; and the Director of the UM Center for Computational Medicine & Bioinformatics. [1] He is the discover of Omenn syndrome, a genetic disorder that is fatal in infancy unless treated. [2] Omenn has served as editor of the Annual Review of Public Health from 1990–1996. [3] and as president of the American Association for the Advancement of Science (AAAS). [4] He has published more than 600 peer-reviewed papers and reviews and is the author or editor of 18 books. [5]

Contents

Education

Omenn received a B.A. from Princeton University (class of 1961) [6] and an M.D. from Harvard Medical School (1965). [7] He interned and did his residency at Massachusetts General Hospital. [8]

Omenn worked with Christian B. Anfinsen at the National Institutes of Health from 1967-1969, [9] doing research as part of military service. [8] In 1969, he joined the University of Washington (UW) in Seattle, Washington as a fellow, working with Arno G. Motulsky in medical genetics. [10] He went on to earn a Ph.D. in genetics from the University of Washington, which he received in 1972. [11]

Career

As a fourth-year student, Omenn studied prenatal diagnosis of inherited conditions. He discovered what is now known as Omenn syndrome, a genetic disorder characterized by the loss of T-cell function. It is generally fatal in infancy, but some cases have responded to treatment. [12] [2] [13]

In 1971 Omenn joined the faculty of medical genetics at the University of Washington. [10] [8] Omenn was appointed as a White House Fellow in 1973-1974, under Presidents Richard Nixon and Gerald Ford. He was one of two staff on Nixon's Project Independence, looking for ways to lessen America's dependence on imported oil. He was also part of a diplomatic mission to convince France not to share nuclear information with Pakistan. [14] Omenn worked with the Atomic Energy Commission on international nuclear policy. [15]

As of 1974 Omenn was first appointed to the National Cancer Advisory Board, as an alternate for Frank Press, Director of the Office of Science and Technology Policy. Omenn's title was Assistant Director of Human Resources, Office of Science and Technology Policy. [16] During 1977-1981, Omenn worked with the Carter administration, first as an assistant to Frank Press, the President's advisor on Science and Technology Policy, and then as Associate Director in the Office of Management and Budget. [8]

Omenn founded the Robert Wood Johnson Clinical Scholars Program at the University of Washington in 1975. [10] He was a Howard Hughes Medical Institute investigator for 1976-1977. [17] He was promoted to a full professorship in medicine in 1979. [10] While at UW, Omenn began working with the Fred Hutchinson Cancer Research Center in Seattle, to conduct clinical trials in cancer prevention. He served as principal investigator of the beta-Carotene and Retinol Efficacy Trial (CARET) seeking preventive agents against lung cancer and heart disease. [18] [19] [20]

In 1981, he was a visiting professor at the Woodrow Wilson School of Princeton University and the Brookings Institution's first Science, Technology, and Policy Fellow. [8] [21]

In 1982, Omenn became Chair of the Department of Environmental & Occupational Health Sciences (DEOHS) and then Dean of the School of Public Health at the University of Washington, serving from 1982-1997. He continues to be an affiliate professor of the university. [22]

In 1982, Omenn and Elaine Faustman at UW introduced a multi-disciplinary course on Risk Assessment and Risk Management. [10] Omenn's work on risk emphasizes science-based risk analysis and the importance of assessing health and ecological risks, communicating information, and reducing risks to health and the environment. [23] From 1982-1988, Omen chaired the National Research Council's Committee on Science, Engineering and Public Policy. [24] From 1990 to 1992, he served on the National Commission on the Environment, resulting in publication of "Choosing a Sustainable Future: The Report of the National Commission on the Environment" (1993). [25] From 1994-1997, Omenn chaired the Presidential/Congressional Commission on Risk Assessment and Risk Management ("Omenn Commission"). [24] [8] The commission was mandated by the Clean Air Act Amendments of 1990, and disbanded as of August 31, 1997. [26] [27]

We are stretching beyond the limits of science to discuss risk. So it is not surprising that scientists disagree on risk estimates or on what should be done, if anything, to reduce those risks. Nevertheless, the public finds such disagreement disconcerting, and the cartoonists mock us!... We need to explain better what is known and what is speculated.– Gilbert Omenn, 1996 [23]

In 1997 Omenn moved to the University of Michigan. [8] From 1997 to 2002 he served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System. [8] [15] In 2015 he was named the Harold T. Shapiro Distinguished University Professor of Medicine. [28]

Omenn was a founder of the international Human Proteome Organization (HUPO) in 2001, a member of the Council of HUPO's pilot Plasma Proteome Project from 2002 through 2010, and chair of the Human Proteome Project from 2010 through 2018. [29] [30] [31]

Omenn is Past President (2005-2006) [32] [4] and Past Chairman of the Board (2006-2007) of the American Association for the Advancement of Science. [33] He is a longtime director of Amgen Inc. and of Rohm & Haas Company. [5] Omenn served as editor of the Annual Review of Public Health from 1990–1996. [3] [34] As of 2020, he joined the Board of Directors of the Foundation for the National Institutes of Health (FNIH). [35]

In 2012, the National Academy of Medicine (NAM) Fellowship program created the Gilbert S. Omenn Fellowship, to be awarded in his name. [36] The inaugural Omenn Fellow was Deidra C. Crews. [37]

Awards

Archives

Related Research Articles

<span class="mw-page-title-main">National Institutes of Health</span> US government medical research agency

The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

<span class="mw-page-title-main">Leroy Hood</span> American biologist (born 1938)

Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA.

<span class="mw-page-title-main">Genetic testing</span> Medical test

Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans, to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.

The National Academy of Medicine (NAM), known as the Institute of Medicine (IoM) until 2015, is an American nonprofit, non-governmental organization. The National Academy of Medicine is a part of the National Academies of Sciences, Engineering, and Medicine, along with the National Academy of Sciences (NAS), National Academy of Engineering (NAE), and the National Research Council (NRC).

<span class="mw-page-title-main">Medical Research Council (United Kingdom)</span> National medical research agency

The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI), which came into operation 1 April 2018, and brings together the UK's seven research councils, Innovate UK and Research England. UK Research and Innovation is answerable to, although politically independent from, the Department for Business, Energy and Industrial Strategy.

<span class="mw-page-title-main">Institute for Systems Biology</span>

Institute for Systems Biology (ISB) is a non-profit research institution located in Seattle, Washington, United States. ISB concentrates on systems biology, the study of relationships and interactions between various parts of biological systems, and advocates an interdisciplinary approach to biological research.

<span class="mw-page-title-main">Mary-Claire King</span> American geneticist

Mary-Claire King is an American geneticist. She was the first to show that breast cancer can be inherited due to mutations in the gene she called BRCA1. She studies human genetics and is particularly interested in genetic heterogeneity and complex traits. She studies the interaction of genetics and environmental influences and their effects on human conditions such as breast and ovarian cancer, inherited deafness, schizophrenia, HIV, systemic lupus erythematosus and rheumatoid arthritis. She has been the American Cancer Society Professor of the Department of Genome Sciences and of Medical Genetics in the Department of Medicine at the University of Washington since 1995.

<span class="mw-page-title-main">Myriad Genetics</span>

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.

<span class="mw-page-title-main">Rick Kittles</span> American geneticist

Rick Antonius Kittles is an American biologist specializing in human genetics and a Senior Vice President for Research at the Morehouse School of Medicine. He is of African-American ancestry, and achieved renown in the 1990s for his pioneering work in tracing the ancestry of African Americans via DNA testing.

Dr. Mary Styles Harris, Ph.D. is an American Biologist and Geneticist, president of Harris & Associates in Atlanta, Georgia, and owner of BioTechnical Communications, which produced the award-winning television documentary “To My Sister…A Gift for Life.”

<i>Annual Review of Public Health</i> Academic journal

The Annual Review of Public Health is a peer-reviewed academic journal that publishes review articles about public health, including epidemiology, biostatistics, occupational safety and health, environmental health, and health policy. It has had three editors: Lester Breslow, Gilbert S. Omenn, and Jonathan E. Fielding.

Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300.

<span class="mw-page-title-main">Edison Liu</span>

Edison T. Liu, M.D. is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). As CEO of The Jackson Laboratory, the organization doubled revenue, faculty and personnel, expanded globally from two campuses to six, established 13 endowed chairs, and increased the institutional endowment by five-fold. He is currently a Professor and Honorary Fellow at the institution. Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.

<span class="mw-page-title-main">Francis Collins</span> American geneticist and director of the National Institutes of Health

Francis Sellers Collins is an American physician-geneticist who discovered the genes associated with a number of diseases and led the Human Genome Project. He is the former director of the National Institutes of Health (NIH) in Bethesda, Maryland, from 17 August 2009 to 19 December 2021, serving under three presidents, and for over 12 years.

Paolo Boffetta is an Italian epidemiologist. He is doing research on cancer and other chronic diseases, where he contributed to the understanding of the role of occupation, environment, alcohol, smoking and nutrition in disease development.

Lester Breslow was an American physician who promoted public health. Breslow's career had a significant impact. He is credited with pioneering chronic disease prevention and health behavior intervention. His work with the Human Population Laboratory in the Alameda County Study established the connection between mortality and lifestyle issues like exercise, diet, sleep, smoking, and alcohol. He has been called "Mr. Public Health".

Arno Gunther Motulsky was a professor of medical genetics and genome sciences at the University of Washington. Through his research, writing and mentoring, he helped create and define the field of medical genetics. He is also known as the "father of pharmacogenomics" based on his report in 1957 of negative drug responses in some patients depending upon their genetics at critical enzymes.[2]

<span class="mw-page-title-main">Bhramar Mukherjee</span> Indian-American biostatistician, data scientist

Bhramar Mukherjee is an Indian-American biostatistician, data scientist, professor and researcher. She is the John D. Kalbfleisch Collegiate Professor and the Chair of Department of Biostatistics, a professor of epidemiology at the University of Michigan. She serves as the associate director for Quantitative Data Sciences at University of Michigan Rogel Cancer Center. She has served as the past Chair for Committee of Presidents of Statistical Societies (COPSS) for a three-year term 2019-2021.

<span class="mw-page-title-main">Wylie Burke</span> American geneticist

Wylie Burke is a Professor Emerita and former Chair of the Department of Bioethics and Humanities at the University of Washington and a founding co-director of the Northwest-Alaska Pharmacogenomics Research Network, which partners with underserved populations in the Pacific Northwest and Alaska.

References

  1. ↑ "Gilbert S. Omenn, M.D., Ph.D." Computational Medicine and Bioinformatics. University of Michigan. 30 March 2016. Retrieved 25 October 2021.
  2. 1 2 Wong, Serre-Yu; Roth, David B. (1 May 2007). "Murine models of Omenn syndrome". Journal of Clinical Investigation. 117 (5): 1213–1216. doi:10.1172/JCI32214. ISSN   0021-9738. PMC   1857244 . PMID   17476351.
  3. 1 2 Omenn, Gilbert S. (1990). "Preface by the Gilbert S. Omenn". Annual Review of Public Health. 11. doi:10.1146/annurev.pu.11.010190.100001.
  4. 1 2 Omenn, Gilbert S. (15 December 2006). "Grand Challenges and Great Opportunities in Science, Technology, and Public Policy". Science. 314 (5806): 1696–1704. doi:10.1126/science.1135003. ISSN   0036-8075. S2CID   153488170 . Retrieved 25 October 2021.
  5. 1 2 "Biography Gilbert S. Omenn, M.D., Ph.D". Galectin Therapeutics Inc. Retrieved 26 October 2021.
  6. ↑ Barnes, Steve (February 24, 2006). "Woodrow Wilson School creates 'Scholars in the Nation's Service' program to encourage government service". Princeton University. Retrieved 25 October 2021.
  7. ↑ "The Gilbert S. Omenn Lecture". Harvard Medical School. Retrieved 25 October 2021.
  8. 1 2 3 4 5 6 7 8 9 "Gilbert S. Omenn chosen as executive V.P. for medical affairs". Michigan News. University of Michigan. September 4, 1997. Retrieved 25 October 2021.
  9. ↑ "Gilbert S. Omenn". The Hastings Center. Retrieved 26 October 2021.
  10. 1 2 3 4 5 Vartan, Starre (2021). "New Labs for a New Era in Public Health". UW Public Health Magazine. Retrieved 25 October 2021.
  11. ↑ The President's Commission on White House Fellows (1969). The White House Fellows . Retrieved 25 October 2021.
  12. 1 2 "Gilbert S. Omenn receives David E. Rogers Award from the American Association of Medical Colleges (AAMC)". Human Genetics. University of Michigan. November 5, 2013. Retrieved 26 October 2021.
  13. ↑ Omenn, Gilbert S. (19 August 1965). "Familial Reticuloendotheliosis with Eosinophilia". New England Journal of Medicine. 273 (8): 427–432. doi:10.1056/NEJM196508192730806. PMID   14328107.
  14. ↑ Kassab, Elizabeth (July 8, 2001). "Regent White to be White House fellow". The Michigan Daily. Retrieved 25 October 2021.
  15. 1 2 Gavin, Kara (March 23, 2017). "Omenn lecture to focus on bridging science and policy world". The University Record. Retrieved 25 October 2021.
  16. ↑ National Cancer Advisory Board (1974). National Cancer Program: Report of the National Cancer Advisory Board Submitted to the President of the United States for Transmittal to the Congress of the United States. Washington, D.C.: U.S. Department of Health, Education and Welfare. Retrieved 26 October 2021.
  17. ↑ "Gilbert S. Omenn, MD, PhD Investigator / 1976—1977". Howard Hughes Medical Institute. Retrieved 25 October 2021.
  18. 1 2 "Dr. Gilbert S. Omenn". American Academy of Arts and Sciences. Retrieved 26 October 2021.
  19. ↑ Omenn, Gilbert S. (1 May 1998). "Chemoprevention of lung cancer: The Rise and Demise of Beta-Carotene". Annual Review of Public Health. 19 (1): 73–99. doi:10.1146/annurev.publhealth.19.1.73. ISSN   0163-7525. PMID   9611613 . Retrieved 26 October 2021.
  20. ↑ Omenn, Gilbert S. (June 2007). "Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future". European Journal of Cancer Prevention. 16 (3): 184–191. doi:10.1097/01.cej.0000215612.98132.18. hdl: 2027.42/86621 . ISSN   0959-8278. PMID   17415088. S2CID   29553114 . Retrieved 26 October 2021.
  21. ↑ Gustafson, Sven (April 4, 2019). "Former U-M Health System CEO: Health care reform will come this year". Special to The Ann Arbor News. Retrieved 25 October 2021.
  22. ↑ Houtz, Jolayne (November 23, 2020). "Omenn-Darling 50th anniversary gift to UW School of Public Health will transform environmental health research". University of Washington News and Events. Retrieved 25 October 2021.
  23. 1 2 National Research Council (1996). "Gilbert S. Omenn, University of Washington". Linking Science and Technology to Society's Environmental Goals. Washington, DC: The National Academies Press. pp. 449–452. doi:10.17226/5409. ISBN   978-0-309-05578-9 . Retrieved 26 October 2021.
  24. 1 2 3 "IOM honors Omenn with medal". University of Michigan Record. October 24, 2008. Retrieved 26 October 2021.
  25. ↑ World Wildlife Fund; National Commission on the Environment (1993). Choosing a Sustainable Future: The Report of the National Commission on the Environment. Island Press. ISBN   9781559632324 . Retrieved 26 October 2021.
  26. ↑ "Presidential Commission on Risk Assessment and Risk Management". EPA. Retrieved 26 October 2021.
  27. ↑ Clarke, David (1995). "The Elusive Middle Ground in Environmental Policy". Issues in Science and Technology. 11 (3): 63–70. ISSN   0748-5492. JSTOR   43311431 . Retrieved 26 October 2021.
  28. ↑ Brown, Kevin (May 21, 2015). "Nine faculty members named Distinguished University Professors". The University Record. Retrieved 25 October 2021.
  29. ↑ Ignjatovic, Vera (1 Feb 2019). "Q&A with Gil Omenn". Human Proteome Organization. University of Melbourne, Australia.
  30. ↑ Michigan Medicine - University of Michigan (10 February 2004). "Scientists Tackle Human Blood Plasma Proteome". NewsWise. Retrieved 25 October 2021.
  31. ↑ Omenn, Gilbert S. (2021). "Reflections on the HUPO Human Proteome Project, the flagship project of the Human Proteome Organization, at 10 years". Molecular & Cellular Proteomics. 20: 100062. doi:10.1016/j.mcpro.2021.100062. ISSN   1535-9476. PMC   8058560 . PMID   33640492 . Retrieved 25 October 2021.
  32. ↑ Pinholster, Ginger (5 May 2015). "Gil Omenn: 'Grand Challenges' Stress Hope, Curiosity". American Association for the Advancement of Science. Retrieved 25 October 2021.
  33. ↑ "AAAS Board of Directors, Officers, and Information" (PDF). American Association for the Advancement of Science. 2007. Retrieved 26 October 2021.
  34. ↑ Omenn, Gilbert S. (1996). "Preface". Annual Review of Public Health. 17. doi:10.1146/annurev.pu.17.031704.100001.
  35. ↑ "Gilbert S. Omenn, M.D., Ph.D., Joins the FNIH Board of Directors". The Foundation for the National Institutes of Health. June 11, 2020. Retrieved 25 October 2021.
  36. ↑ "Gilbert S. Omenn Fellowship". Association of Schools and Programs of Public Health (ASPPH). January 25, 2019. Retrieved 26 October 2021.
  37. ↑ "Gilbert S. Omenn Fellowship". National Academy of Medicine. Retrieved 26 October 2021.
  38. ↑ "Amesite Inc. Strengthens Commitment to Supporting Online Learning in the Healthcare Sector with the Appointment of Gilbert S. Omenn". Amesite Inc. March 9, 2020. Retrieved 26 October 2021.
  39. ↑ "Walsh McDermott Medal – Past Recipients". National Academy of Medicine. Retrieved 26 October 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.